Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UNLOCK-EPIBREAST prifetrastat plus fulvestrant in advanced HR-positive/HER2-negative breast cancer
2025-521982-29-00Phase 2Authorised
- Sponsor
- Unicancer
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of prifetrastat and fulvestrant in breast cancer, sponsored by Unicancer. Primary endpoint: ctDNA tumor fraction reduction. Planned start May 2026; status: authorised.
02
Drugs
prifetrastatfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2025-521982-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521982-29-00.